Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel

Cancer Letters

Volumn 160, Issue 1, 2000, Pages 9-12

  Ota, Shunichiro ^a   Sugiyama, Toru ^a   Ushijima, Kimio ^a   Komai, Kan ^a   Fujiyoshi, Keizo ^a   Hirai, Nobuyuki ^a   Nishida, Takashi ^a   Kamura, Toshiharu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Paclitaxel; Platinum resistant; Recurrent endometrial cancer; Taxol

Indexed keywords

CISPLATIN; TAXOL;

ADULT; ALOPECIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOXICITY; ENDOMETRIUM CANCER; FEMALE; INFUSION; LEUKOPENIA; LUNG; MALE; MYALGIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA-125 ANTIGEN; CASE REPORT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMAN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 0034634748     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00548-6     Document Type: Article

References (14)

1. Park R.C., Grisby P.W., Muss H.B. Corpus: epithelial tumors. Hoskins W.J., Perez C.A., Young R.C., et al. Principles and Practice of Gynecologic Oncology. 1992;663-693 Saunders, Philadelphia, PA.
2. Muss H.B. Chemotherapy of metastatic endometrial cancer. Semin. Oncol. 21:1994;107-113.
3. Moore T.D., Phillips P.H., Nerenstone S.R., Cheson B.D. Systemic treatment of advanced andrecurrent endometrial carcinoma: current status and future directions. J. Clin. Oncol. 9:1991;1071-1088.
4. Turbow M.M., Ballon S.C., Sikic B.I., Koretz M.M. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. Cancer Treat. Rep. 69:1985;465-469.
5. Hancock K.C., Freedman R.S., Edwards C.L. Rutledge FN Use of cisplatin, doxorubicin and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat. Rep. 70:1986;789-791.
6. Ball H.G., Blessing J.A., Lentz S.S., Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a gynecologic oncology group study. Gynecol. Oncol. 62:1996;278-281.
7. Woo H.L., Swenerton K.D., Hoskins P.J. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am. J. Clin. Oncol. 19:1996;290-291.
8. Lissoni A., Zanetta G., Losa G., Gabriele A., Parma G. Mangioni C Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann. Oncol. 7:1996;861-863.
9. Liebmann J.E., Cook J.A., Lipshultz C. Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br. J. Cancer. 68:1993;1104-1109.
10. Andersson H., Horvath G., Mellquist L., Westberg R. Taxol given weekly in advanced previously treated ovarian carcinomas: a pilot study. Int. J. Gynecol. Cancer. 7:1997;262-266.
11. Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenizie M., O'Connor C. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15:1997;187-192.
12. Bookman M.A., Kloth D.D., Kover P.E., Smolinski S., Ozols R.F. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin. Oncol. 24:1997;13-15.
13. Hainsworth J.D., Hopkins M., Thomas F., Tong W., Norton L., Spriggs D. Taxol administered by 1-hour infusion: preliminary results of a phase I-II study comparing two dose schedules. Proc. Am. Soc. Clin. Oncol. 13:(155):1994;413.
14. Loffler T.M., Freund W., Lipke J., Hausamen T.U. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin. Oncol. 23:1996;32-34.